GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (FRA:RI2) » Definitions » Gross Profit

Rigel Pharmaceuticals (FRA:RI2) Gross Profit : €128.9 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Rigel Pharmaceuticals Gross Profit?

Rigel Pharmaceuticals's gross profit for the three months ended in Sep. 2024 was €42.6 Mil. Rigel Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was €128.9 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Rigel Pharmaceuticals's gross profit for the three months ended in Sep. 2024 was €42.6 Mil. Rigel Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was €49.8 Mil. Therefore, Rigel Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2024 was 85.49%.

Rigel Pharmaceuticals had a gross margin of 85.49% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Rigel Pharmaceuticals was 99.36%. The lowest was 89.43%. And the median was 98.87%.


Rigel Pharmaceuticals Gross Profit Historical Data

The historical data trend for Rigel Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Gross Profit Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.54 88.55 131.12 111.86 100.66

Rigel Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.17 29.35 25.31 31.62 42.60

Competitive Comparison of Rigel Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Rigel Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Gross Profit falls into.



Rigel Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Rigel Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=107.181 - 6.52
=100.7

Rigel Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=49.832 - 7.232
=42.6

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €128.9 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Rigel Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=42.6 / 49.832
=85.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Rigel Pharmaceuticals  (FRA:RI2) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Rigel Pharmaceuticals had a gross margin of 85.49% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Rigel Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals Headlines

No Headlines